Annual Book Value
$10.98 M
$9.83 M-47.81%
31 December 2023
Summary:
Inhibikase Therapeutics annual book value is currently $10.98 million, with the most recent change of +$9.83 million (-47.81%) on 31 December 2023. During the last 3 years, it has risen by +$1.19 million (+12.20%). IKT annual book value is now -71.42% below its all-time high of $38.42 million, reached on 31 December 2021.IKT Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Book Value
-$530.60 K
-$5.63 M-110.41%
30 September 2024
Summary:
Inhibikase Therapeutics quarterly book value is currently -$530.60 thousand, with the most recent change of -$5.63 million (-110.41%) on 30 September 2024. Over the past year, it has dropped by -$15.55 million (-103.53%). IKT quarterly book value is now -101.13% below its all-time high of $47.05 million, reached on 30 June 2021.IKT Quarterly Book Value Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IKT Book Value Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -47.8% | -103.5% |
3 y3 years | +12.2% | -101.2% |
5 y5 years | +1511.0% | - |
IKT Book Value High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -71.4% | +12.2% | -101.2% | at low |
5 y | 5 years | -71.4% | +344.5% | -101.1% | +89.7% |
alltime | all time | -71.4% | +344.5% | -101.1% | +89.7% |
Inhibikase Therapeutics Book Value History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | -$530.60 K(-110.4%) |
June 2024 | - | $5.10 M(-24.8%) |
Mar 2024 | - | $6.78 M(-38.3%) |
Dec 2023 | $10.98 M(-47.8%) | $10.98 M(-26.9%) |
Sept 2023 | - | $15.02 M(-22.8%) |
June 2023 | - | $19.46 M(-23.1%) |
Mar 2023 | - | $25.32 M(+20.4%) |
Dec 2022 | $21.04 M | $21.04 M(-16.3%) |
Sept 2022 | - | $25.14 M(-14.8%) |
June 2022 | - | $29.50 M(-13.3%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2022 | - | $34.01 M(-11.5%) |
Dec 2021 | $38.42 M(+292.6%) | $38.42 M(-11.0%) |
Sept 2021 | - | $43.16 M(-8.3%) |
June 2021 | - | $47.05 M(+485.5%) |
Mar 2021 | - | $8.04 M(-17.9%) |
Dec 2020 | $9.78 M(-317.9%) | $9.78 M(-290.9%) |
Sept 2020 | - | -$5.13 M(+6.1%) |
June 2020 | - | -$4.83 M(+2.7%) |
Mar 2020 | - | -$4.70 M(+4.7%) |
Dec 2019 | -$4.49 M(+477.1%) | -$4.49 M |
Dec 2018 | -$778.00 K | - |
FAQ
- What is Inhibikase Therapeutics annual book value?
- What is the all time high annual book value for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics annual book value year-on-year change?
- What is Inhibikase Therapeutics quarterly book value?
- What is the all time high quarterly book value for Inhibikase Therapeutics?
- What is Inhibikase Therapeutics quarterly book value year-on-year change?
What is Inhibikase Therapeutics annual book value?
The current annual book value of IKT is $10.98 M
What is the all time high annual book value for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high annual book value is $38.42 M
What is Inhibikase Therapeutics annual book value year-on-year change?
Over the past year, IKT annual book value has changed by -$10.06 M (-47.81%)
What is Inhibikase Therapeutics quarterly book value?
The current quarterly book value of IKT is -$530.60 K
What is the all time high quarterly book value for Inhibikase Therapeutics?
Inhibikase Therapeutics all-time high quarterly book value is $47.05 M
What is Inhibikase Therapeutics quarterly book value year-on-year change?
Over the past year, IKT quarterly book value has changed by -$15.55 M (-103.53%)